IDR 246.0
(2.5%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 7.46 Billion IDR | -94.21% |
2022 | 128.93 Billion IDR | -59.12% |
2021 | 315.36 Billion IDR | 166.22% |
2020 | 118.46 Billion IDR | 278.26% |
2019 | 31.31 Billion IDR | 510.72% |
2018 | 5.12 Billion IDR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | 10.86 Billion IDR | 766.14% |
2024 Q2 | 93.49 Million IDR | -99.14% |
2024 Q3 | 831.52 Million IDR | 789.37% |
2023 Q3 | 1.94 Billion IDR | 134.19% |
2023 FY | 7.46 Billion IDR | -94.21% |
2023 Q4 | 1.25 Billion IDR | -35.52% |
2023 Q2 | -5.69 Billion IDR | -139.05% |
2023 Q1 | 14.57 Billion IDR | -29.5% |
2022 Q2 | 38.33 Billion IDR | -5.59% |
2022 Q1 | 40.6 Billion IDR | 74.72% |
2022 FY | 128.93 Billion IDR | -59.12% |
2022 Q4 | 20.68 Billion IDR | -29.43% |
2022 Q3 | 29.3 Billion IDR | -23.57% |
2021 Q2 | 70.53 Billion IDR | 9.8% |
2021 Q4 | 23.24 Billion IDR | -59.42% |
2021 Q3 | 57.27 Billion IDR | -18.8% |
2021 Q1 | 64.24 Billion IDR | 185.75% |
2021 FY | 315.36 Billion IDR | 166.22% |
2020 FY | 118.46 Billion IDR | 278.26% |
2020 Q1 | 7.9 Billion IDR | 0.0% |
2020 Q4 | 22.48 Billion IDR | -55.48% |
2020 Q3 | 50.49 Billion IDR | 538.8% |
2020 Q2 | 7.9 Billion IDR | 0.0% |
2019 FY | 31.31 Billion IDR | 510.72% |
2018 FY | 5.12 Billion IDR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
PT Metro Healthcare Indonesia Tbk | -110.91 Billion IDR | 106.727% |
PT Medikaloka Hermina Tbk | 437.34 Billion IDR | 98.294% |
PT Mitra Keluarga Karyasehat Tbk | 916.13 Billion IDR | 99.186% |
PT Murni Sadar Tbk | -12.83 Billion IDR | 158.146% |
PT Famon Awal Bros Sedaya Tbk | 216.97 Billion IDR | 96.561% |
PT Royal Prima Tbk | -2.74 Billion IDR | 371.66% |
PT Kedoya Adyaraya Tbk | 25.18 Billion IDR | 70.379% |
PT Sarana Meditama Metropolitan Tbk | 12.25 Billion IDR | 39.104% |
PT Siloam International Hospitals Tbk | 1211.28 Billion IDR | 99.384% |
PT Sejahteraraya Anugrahjaya Tbk | -38.49 Billion IDR | 119.385% |